Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Apr;111(4):1342–1346. doi: 10.1111/j.1476-5381.1994.tb14892.x

Investigation of the specificity of FK 888 as a tachykinin NK1 receptor antagonist.

Z Y Wang 1, S R Tung 1, G R Strichartz 1, R Håkanson 1
PMCID: PMC1910150  PMID: 7518299

Abstract

1. A recently described peptide tachykinin (NK1) receptor antagonist, FK 888, was found to inhibit the electrically-evoked, tachykinin-mediated contractile responses of the rabbit iris sphincter in a concentration-dependent manner; the pIC50 value was 6.6 +/- 0.08. 2. Contractions induced by a selective NK1 receptor agonist, [Sar9,Met(O2)11]substance P, were inhibited competitively by FK 888; the pKB value was 7.1. 3. FK 888 (1 nM-100 microM) was without effect on the electrically-evoked, cholinergic response of the rabbit iris sphincter and the electrically-evoked, sympathetic response of the guinea-pig vas deferens. The contractions of the rabbit iris sphincter, induced by either carbachol (10 nM-30 microM) or noradrenaline (0.1-100 microM), were not affected by 10 microM FK 888. 4. FK 888 (1-30 microM) did not induce histamine release from rat peritoneal mast cells. 5. FK 888 (33 and 333 microM) was without effect on the electrically-evoked action potentials of the frog sciatic nerve. Thus, FK 888 is a moderately high affinity and selective tachykinin (NK1) receptor antagonist.

Full text

PDF
1342

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Caeser M., Seabrook G. R., Kemp J. A. Block of voltage-dependent sodium currents by the substance P receptor antagonist (+/-)-CP-96,345 in neurones cultured from rat cortex. Br J Pharmacol. 1993 Aug;109(4):918–924. doi: 10.1111/j.1476-5381.1993.tb13708.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Folkers K., Feng D. M., Asano N., Håkanson R., Weisenfeld-Hallin Z., Leander S. Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4833–4835. doi: 10.1073/pnas.87.12.4833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Folkers K., Håkanson R., Hörig J., Xu J. C., Leander S. Biological evaluation of substance P antagonists. Br J Pharmacol. 1984 Oct;83(2):449–456. doi: 10.1111/j.1476-5381.1984.tb16506.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fujii T., Murai M., Morimoto H., Maeda Y., Yamaoka M., Hagiwara D., Miyake H., Ikari N., Matsuo M. Pharmacological profile of a high affinity dipeptide NK1 receptor antagonist, FK888. Br J Pharmacol. 1992 Nov;107(3):785–789. doi: 10.1111/j.1476-5381.1992.tb14524.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fujiwara M., Hayashi H., Muramatsu I., Ueda N. Supersensitivity of the rabbit iris sphincter muscle induced by trigeminal denervation: the role of substance P. J Physiol. 1984 May;350:583–597. doi: 10.1113/jphysiol.1984.sp015219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gamse R., Petsche U., Lembeck F., Jancsò G. Capsaicin applied to peripheral nerve inhibits axoplasmic transport of substance P and somatostatin. Brain Res. 1982 May 13;239(2):447–462. doi: 10.1016/0006-8993(82)90521-2. [DOI] [PubMed] [Google Scholar]
  7. Garret C., Carruette A., Fardin V., Moussaoui S., Peyronel J. F., Blanchard J. C., Laduron P. M. Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10208–10212. doi: 10.1073/pnas.88.22.10208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Guard S., Boyle S. J., Tang K. W., Watling K. J., McKnight A. T., Woodruff G. N. The interaction of the NK1 receptor antagonist CP-96,345 with L-type calcium channels and its functional consequences. Br J Pharmacol. 1993 Sep;110(1):385–391. doi: 10.1111/j.1476-5381.1993.tb13821.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hall J. M., Caulfield M. P., Watson S. P., Guard S. Receptor subtypes or species homologues: relevance to drug discovery. Trends Pharmacol Sci. 1993 Oct;14(10):376–383. doi: 10.1016/0165-6147(93)90096-3. [DOI] [PubMed] [Google Scholar]
  10. Hall J. M., Mitchell D., Morton I. K. Does substance P release mediate NANC nerve-mediated responses to field stimulation and ligands, in the rabbit isolated sphincter pupillae? Regul Pept. 1993 Jul 2;46(1-2):278–281. doi: 10.1016/0167-0115(93)90059-h. [DOI] [PubMed] [Google Scholar]
  11. Hall J. M., Mitchell D., Morton I. K. Neurokinin receptors in the rabbit iris sphincter characterised by novel agonist ligands. Eur J Pharmacol. 1991 Jun 18;199(1):9–14. doi: 10.1016/0014-2999(91)90630-9. [DOI] [PubMed] [Google Scholar]
  12. Hall J. M., Mitchell D., Morton I. K. Tachykinin receptors mediating responses to sensory nerve stimulation and exogenous tachykinins and analogues in the rabbit isolated iris sphincter. Br J Pharmacol. 1993 Aug;109(4):1008–1013. doi: 10.1111/j.1476-5381.1993.tb13721.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hirayama Y., Lei Y. H., Barnes P. J., Rogers D. F. Effects of two novel tachykinin antagonists, FK224 and FK888, on neurogenic airway plasma exudation, bronchoconstriction and systemic hypotension in guinea-pigs in vivo. Br J Pharmacol. 1993 Mar;108(3):844–851. doi: 10.1111/j.1476-5381.1993.tb12888.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Håkanson R., Beding B., Ekman R., Heilig M., Wahlestedt C., Sundler F. Multiple tachykinin pools in sensory nerve fibres in the rabbit iris. Neuroscience. 1987 Jun;21(3):943–950. doi: 10.1016/0306-4522(87)90049-2. [DOI] [PubMed] [Google Scholar]
  15. Håkanson R., Leander S., Andersson R. G., Hörig J. Substance P antagonists release histamine from peritoneal mast cells. Acta Physiol Scand. 1983 Feb;117(2):319–320. doi: 10.1111/j.1748-1716.1983.tb07215.x. [DOI] [PubMed] [Google Scholar]
  16. Håkanson R., Leander S., Asano N., Feng D. M., Folkers K. Spantide II, a novel tachykinin antagonist having high potency and low histamine-releasing effect. Regul Pept. 1990 Oct 29;31(1):75–82. doi: 10.1016/0167-0115(90)90197-5. [DOI] [PubMed] [Google Scholar]
  17. Håkanson R., Rönnberg A. L. Improved fluorometric assay of histamine: condensation with O-phthalaldehyde at -20 degrees C. Anal Biochem. 1974 Aug;60(2):560–567. doi: 10.1016/0003-2697(74)90267-x. [DOI] [PubMed] [Google Scholar]
  18. Håkanson R., Wang Z. Y., Folkers K. Comparison of spantide II and CP-96,345 for blockade of tachykinin-evoked contractions of smooth muscle. Biochem Biophys Res Commun. 1991 Jul 15;178(1):297–301. doi: 10.1016/0006-291x(91)91813-r. [DOI] [PubMed] [Google Scholar]
  19. Kenakin T. P. The classification of drugs and drug receptors in isolated tissues. Pharmacol Rev. 1984 Sep;36(3):165–222. [PubMed] [Google Scholar]
  20. Kurose M., Saeki K. Histamine release induced by neurotensin from rat peritoneal mast cells. Eur J Pharmacol. 1981 Dec 3;76(2-3):129–136. doi: 10.1016/0014-2999(81)90494-5. [DOI] [PubMed] [Google Scholar]
  21. Lecci A., Giuliani S., Patacchini R., Viti G., Maggi C. A. Role of NK1 tachykinin receptors in thermonociception: effect of (+/-)-CP 96,345, a non-peptide substance P antagonist, on the hot plate test in mice. Neurosci Lett. 1991 Aug 19;129(2):299–302. doi: 10.1016/0304-3940(91)90485-c. [DOI] [PubMed] [Google Scholar]
  22. Maggi C. A., Patacchini R., Rovero P., Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol. 1993 Feb;13(1):23–93. doi: 10.1111/j.1474-8673.1993.tb00396.x. [DOI] [PubMed] [Google Scholar]
  23. Maggio J. E. Tachykinins. Annu Rev Neurosci. 1988;11:13–28. doi: 10.1146/annurev.ne.11.030188.000305. [DOI] [PubMed] [Google Scholar]
  24. Nagahisa A., Asai R., Kanai Y., Murase A., Tsuchiya-Nakagaki M., Nakagaki T., Shieh T. C., Taniguchi K. Non-specific activity of (+/-)-CP-96,345 in models of pain and inflammation. Br J Pharmacol. 1992 Oct;107(2):273–275. doi: 10.1111/j.1476-5381.1992.tb12737.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Otsuka M., Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev. 1993 Apr;73(2):229–308. doi: 10.1152/physrev.1993.73.2.229. [DOI] [PubMed] [Google Scholar]
  26. Post C., Butterworth J. F., Strichartz G. R., Karlsson J. A., Persson C. G. Tachykinin antagonists have potent local anaesthetic actions. Eur J Pharmacol. 1985 Nov 19;117(3):347–354. doi: 10.1016/0014-2999(85)90008-1. [DOI] [PubMed] [Google Scholar]
  27. Regoli D., Drapeau G., Dion S., Couture R. New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. Trends Pharmacol Sci. 1988 Aug;9(8):290–295. doi: 10.1016/0165-6147(88)90013-2. [DOI] [PubMed] [Google Scholar]
  28. Snider R. M., Constantine J. W., Lowe J. A., 3rd, Longo K. P., Lebel W. S., Woody H. A., Drozda S. E., Desai M. C., Vinick F. J., Spencer R. W. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science. 1991 Jan 25;251(4992):435–437. doi: 10.1126/science.1703323. [DOI] [PubMed] [Google Scholar]
  29. Stjernquist M., Håkanson R., Leander S., Owman C., Sundler F., Uddman R. Immunohistochemical localization of substance P, vasoactive intestinal polypeptide and gastrin-releasing peptide in vas deferens and seminal vesicle, and the effect of these and eight other neuropeptides on resting tension and neurally evoked contractile activity. Regul Pept. 1983 Sep;7(1):67–86. doi: 10.1016/0167-0115(83)90282-3. [DOI] [PubMed] [Google Scholar]
  30. Tamura K., Mutabagani K., Wood J. D. Analysis of a nonpeptide antagonist for substance P on myenteric neurons of guinea-pig small intestine. Eur J Pharmacol. 1993 Mar 2;232(2-3):235–239. doi: 10.1016/0014-2999(93)90779-h. [DOI] [PubMed] [Google Scholar]
  31. Wahlestedt C., Bynke G., Beding B., von Leithner P., Håkanson R. Neurogenic mechanisms in control of the rabbit iris sphincter muscle. Eur J Pharmacol. 1985 Nov 19;117(3):303–309. doi: 10.1016/0014-2999(85)90003-2. [DOI] [PubMed] [Google Scholar]
  32. Wang Z. Y., Håkanson R. (+/-)-CP-96,345, a selective tachykinin NK1 receptor antagonist, has non-specific actions on neurotransmission. Br J Pharmacol. 1992 Nov;107(3):762–765. doi: 10.1111/j.1476-5381.1992.tb14520.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wang Z. Y., Håkanson R. The electrically evoked, tachykinin-mediated contractile response of the isolated rabbit iris sphincter muscle involves NK1 receptors only. Eur J Pharmacol. 1992 Jun 5;216(2):327–329. doi: 10.1016/0014-2999(92)90380-m. [DOI] [PubMed] [Google Scholar]
  34. Wang Z. Y., Håkanson R. The rabbit iris sphincter contains NK1 and NK3 but not NK2 receptors: a study with selective agonists and antagonists. Regul Pept. 1993 Apr 8;44(3):269–275. doi: 10.1016/0167-0115(93)90136-v. [DOI] [PubMed] [Google Scholar]
  35. Wang Z. Y., Tung S. R., Strichartz G. R., Håkanson R. Non-specific actions of the non-peptide tachykinin receptor antagonists, CP-96,345, RP 67580 and SR 48968, on neurotransmission. Br J Pharmacol. 1994 Jan;111(1):179–184. doi: 10.1111/j.1476-5381.1994.tb14041.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Watling K. J. Nonpeptide antagonists herald new era in tachykinin research. Trends Pharmacol Sci. 1992 Jul;13(7):266–269. doi: 10.1016/0165-6147(92)90082-h. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES